Income statement
USD
Annual
| Metric | 2024 | 2023 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 4M | 0 |
| Gross Profit | 0 | 0 | 239K | 702K | 0 |
| Operating Income | -18K | -6K | -5M | -9M | -2M |
| EBITDA | -18K | -6K | -5M | -10M | -2M |
| Net Income | -18K | -6K | -9M | -13M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0015
+0.00% today
1Y Change
-98.33%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tristar Wellness Solutions Inc. (TWSI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 98.3% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -100.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 1.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TWSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TWSI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TWSI Max Drawdown
-99.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TWSI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$2.2M
+82.2% YoY
Free Cash Flow
-$592.1K
-1532.4% YoY
Revenue Growth
+0.0%
EPS Growth
-100.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 4M | 0 |
| Gross Profit | 0 | 0 | 239K | 702K | 0 |
| Operating Income | -18K | -6K | -5M | -9M | -2M |
| EBITDA | -18K | -6K | -5M | -10M | -2M |
| Net Income | -18K | -6K | -9M | -13M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Cash & Equivalents | 189K | 193K | 11K | 0 | 98K |
| Total Assets | 3M | 6M | 24K | 6K | 1M |
| Total Liabilities | 14M | 9M | 893K | 2M | 3M |
| Shareholder Equity | -11M | -4M | -869K | -2M | -2M |
| Total Debt | 10M | 5M | 575K | 893K | 878K |
| Net Debt | 9M | 5M | 564K | 893K | 780K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
592K
-1532.4% YoY
Capital Expenditures
5
Free Cash Flow
592K
-1532.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.3%
Debt / Equity
-0.86x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.